Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOLMA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOlema Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 19, 2020
āļāļĩāļāļĩāđāļBohen (Sean P)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ96
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 19
āļāļĩāđāļāļĒāļđāđ780 Brannan Street
āđāļĄāļ·āļāļSAN FRANCISCO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94103
āđāļāļĢāļĻāļąāļāļāđ14156513316
āđāļ§āđāļāđāļāļāđhttps://olema.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOLMA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 19, 2020
āļāļĩāļāļĩāđāļBohen (Sean P)
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Scientific Officer
Mr. Andrew Rappaport
Independent Director
Ms. Cynthia M. Butitta
Independent Director
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Mr. Jason Obyrne
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Ms. Courtney O'Konek
Vice President, Corporate Communications
Vice President, Corporate Communications
Dr. Prakash Raman, Ph.D.
Independent Director
Ms. Shawnte M. Mitchell, J.D.
Ms. Shawnte M. Mitchell, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
Mr. Scott Garland
Independent Director
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Scientific Officer
Mr. Andrew Rappaport
Independent Director
Ms. Cynthia M. Butitta
Independent Director
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Mr. Jason Obyrne
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Ms. Courtney O'Konek
Vice President, Corporate Communications
Vice President, Corporate Communications